Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Rated “Buy” by Sell-Side Brokerages

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have received an average recommendation of “Buy” from the ten research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $15.86.

A number of research firms have recently commented on IVA. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Friday, July 17th. Cantor Fitzgerald began coverage on Inventiva in a report on Friday, July 17th. They issued an “overweight” rating for the company. Truist Financial increased their price target on Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Wall Street Zen raised Inventiva from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Piper Sandler restated an “overweight” rating on shares of Inventiva in a research report on Wednesday, September 16th.

Inventiva Trading Down 2.6%

IVA opened at $3.37 on Thursday. The firm has a fifty day moving average price of $4.26 and a 200 day moving average price of $4.60. Inventiva has a 1 year low of $3.11 and a 1 year high of $7.98.

Inventiva (NASDAQ:IVA) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.75 million for the quarter. On average, research analysts forecast that Inventiva will post -0.81 EPS for the current year.

Institutional Investors Weigh In On Inventiva

Institutional investors have recently added to or reduced their stakes in the stock. NEXTBio Capital Management LP acquired a new position in Inventiva during the fourth quarter worth $6,039,000. Propel Bio Management LLC acquired a new stake in shares of Inventiva in the fourth quarter valued at about $4,650,000. Eventide Asset Management LLC acquired a new stake in shares of Inventiva in the fourth quarter valued at about $1,155,000. Seven Fleet Capital Management LP purchased a new stake in shares of Inventiva during the first quarter worth about $1,111,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Inventiva during the 4th quarter worth about $603,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Dijon, France. The company develops oral small-molecule therapies for chronic metabolic and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an investigational pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.